Clinical trials: Teicoplanin-based Antimicrobial Therapy
Teicoplanin-based Antimicrobial Therapy, Staphylococcus Aureus
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance.
- Conditions
- Teicoplanin-based Antimicrobial Therapy, Staphylococcus Aureus, Bone and Joint Infection
- Trial name
- NCT03177369
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon